1065267-14-2

Basic information

• Product Name: (3,5-difluoropyridin-2-yl)Methanol
• Synonyms: (3,5-difluoropyridin-2-yl)Methanol;2-Pyridinemethanol, 3,5-difluoro-
• CAS NO: 1065267-14-2
• Molecular Formula: C₆H₅F₂NO
• Molecular Weight: 145.1068064
• Mol File: 1065267-14-2.mol

Chemical Properties

• Boiling Point: 176.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.383±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.34±0.10(Predicted)
• CAS DataBase Reference: (3,5-difluoropyridin-2-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3,5-difluoropyridin-2-yl)Methanol(1065267-14-2)
• EPA Substance Registry System: (3,5-difluoropyridin-2-yl)Methanol(1065267-14-2)

Safety Data

• Hazardous Substances Data: 1065267-14-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(3,5-difluoropyridin-2-yl)Methanol serves as a crucial building block in the development of pharmaceuticals. Its unique structure and reactivity allow for the creation of novel drug candidates with potential therapeutic applications.
Used in Agrochemical Production:
(3,5-difluoropyridin-2-yl)Methanol also finds application in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products designed to improve crop yields and protect plants from pests.
Used in Specialty Chemicals and Materials:
(3,5-difluoropyridin-2-yl)Methanol is utilized in the production of specialty chemicals and materials, where its distinctive properties can be harnessed to create innovative products with specific applications in various industries.

Upstream product

• 1065267-10-8 3,5-difluoro-pyridine-2-carboxylic acid ethyl ester 
• 1033202-51-5 5-fluoro-3-nitropyridine-2-carbonitrile 
• 1052714-11-0 3-amino-5-fluoropyridine-2-carboxylic acid methyl ester 
• 1374115-60-2 3-amino-5-fluoropicolinonitrile 
• 298709-29-2 3,5-difluoropyridine-2-carbonitrile 
• 955885-64-0 methyl 3,5-difluoropyridine-2-carboxylate 
• 745784-04-7 3,5-difluoropyridine-2-carboxylic acid 

Downstream Products

• 780801-58-3 3,5-difluoropicolinaldehyde 
• 1442451-89-9 5-chloro-6-((3,5-difluoropyridin-2-yl)methoxy)-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-2-methylphenyl)-2-methylpyrimidin-4(3H)-one 
• 1222633-85-3 2-(chloromethyl)-3,5-difluoropyridine 
• 1428987-10-3 (3,5-Difluoropyridin-2-yl)methyl 4-methylbenzenesulfonate 

Relevant articles and documents

PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS

The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, inclu

NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS

Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.

PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS

Pyrido[2,3-d]pyrimidin-4-one compounds, formulations containing those compounds, and their use as tankyrase 1 and 2 inhibitors Formula (I).

METHYL/FLUORO-PYRIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS AND FLUORO-PYRIMIDINYL-METHOXY SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS

The present disclosure provides methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and auto-inflammatory disease, including rheumatoid arthritis, having the structure of Formula (I): wherein R1, R2, R3, R4, R5 and X are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS

The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.

3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS

A compound of Formula (I) or a pharmaceutically acceptable salt thereof: (I), Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, -CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER

The present invention relates to compounds of Formula (I): and to their pharmaceutical compositions, and to their methods of use. These novel compounds provide a treatment for myeloproliferative disorders and cancer.